Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients

被引：3
|
作者：
Yue, D. [1 ]
Xu, S. [2 ]
Wang, Q. [3 ]
Li, X. [4 ]
Shen, Y. [5 ]
Zhao, H. [6 ]
Chen, C. [7 ]
Mao, W. [8 ]
Liu, W. [9 ]
Liu, J. [10 ]
Zhang, L. [11 ]
Ma, H. [12 ]
Li, Q. [13 ]
Yang, Y. [14 ]
Liu, Y. [15 ]
Chen, H. [16 ]
Wang, C. [1 ]
机构：
[1] Tianjin Med Univ, Canc Inst & Hosp, Canc Inst & Hosp, Tianjin, Peoples R China
[2] Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[4] Fourth Mil Med Univ, Tangdu Hosp, XiAn Hosp, Xian, Shaanxi, Peoples R China
[5] Qing Dao Univ, Hosp 1, Qingdao, Shandong, Peoples R China
[6] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[7] Fujian Med Univ, Union Hosp, Fuzhou, Fujian, Peoples R China
[8] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[9] Jilin Univ, Bethune Hosp 1, Changchun, Jilin, Peoples R China
[10] Tumor Hosp Hebei Prov, Shijiazhuang, Hebei, Peoples R China
[11] Sun Yat Sen Univ, Canc Hosp, Guangzhou, Guangdong, Peoples R China
[12] Suzhou Univ, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China
[13] Sichuan Canc Hosp & Inst, Chengdu, Sichuan, Peoples R China
[14] Peking Univ, Canc Hosp, Beijing, Peoples R China
[15] Liaoning Canc Hosp, Shenyang, Tianjin, Peoples R China
[16] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Adjuvant therapy; Erlotinib; EGFR mutation;
D O I：
10.1016/j.jtho.2017.09.423
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA 16.04
引用
收藏
页码：S1789 / S1789
页数：1
相关论文
共 50 条
  • [1] Erlotinib as adjuvant therapy in EGFR-mutant NSCLC
    Jassem, Jacek
    LANCET RESPIRATORY MEDICINE, 2018, 6 (11): : 808 - 810
  • [2] Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC
    Remon, Jordi
    Hendriks, Lizza E. L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 368 - 370
  • [3] Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR plus NSCLC.
    Yue, Dongsheng
    Xu, Shi-Dong
    Wang, Qun
    Li, Xiaofei
    Shen, Yi
    Zhao, Heng
    Chen, Chun
    Mao, Weimin
    Liu, Wei
    Liu, Junfeng
    Zhang, Lan-Jun
    Ma, Haitao
    Li, Qiang
    Yang, Yue
    Liu, Yongyu
    Chen, Haiquan
    Zhang, Zhenfa
    Zhang, Bin
    Gong, Fuyu
    Wang, Changli
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Aumolertinib Versus Erlotinib/Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER)
    Liang, W.
    Xu, E.
    Zhao, J.
    Wang, M.
    Zhang, Z.
    Liang, Y.
    Cheng, C.
    Wang, G.
    Zhong, C.
    Liang, Z.
    Chen, X.
    Zheng, B.
    Huang, Y.
    Hu, J.
    Xu, L.
    Xie, M.
    Liang, N.
    Xu, S.
    Liu, J.
    Wei, L.
    Peng, Z.
    Zhang, G.
    Zhang, S.
    Xu, S.
    He, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S285 - S286
  • [5] Audit of adjuvant vinorelbine and cisplatin for patients with resected NSCLC
    Alzouebi, M.
    Fisher, P.
    Woll, P. J.
    Hatton, M. Q.
    Foran, B.
    Mohanamurali, J.
    Danson, S.
    LUNG CANCER, 2010, 67 : S3 - S3
  • [6] Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC
    Kian, W.
    Roisman, L. C.
    Dudnik, J.
    Chernomordikov, L.
    Allen, A. M.
    Corn, B.
    Dudnik, E.
    Rosenberg, S. K.
    Zemel, M.
    Lavrenkov, K.
    Peled, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S941 - S941
  • [7] Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial
    Yue, Dongsheng
    Xu, Shidong
    Wang, Qun
    Li, Xiaofei
    Shen, Yi
    Zhao, Heng
    Chen, Chun
    Mao, Weimin
    Liu, Wei
    Liu, Junfeng
    Zhang, Lanjun
    Ma, Haito
    Li, Qiang
    Yang, Yue
    Liu, Yongyu
    Chen, Haiquan
    Wang, Changli
    LANCET RESPIRATORY MEDICINE, 2018, 6 (11): : 863 - 873
  • [8] Erlotinib in EGFR-Positive NSCLC: Efficacy, Safety and Feasibility for Rebiopsy
    Trigo, Manuel
    Oramas, Juana
    Aguilar, David
    De Castro, Javier
    Laura Ortega, An
    Majem, Margarita
    Esteban, Emilio
    Esteban, Beatriz
    Garcia-Bernaldez, Cristina
    Gordo, Rocio
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S660 - S660
  • [9] Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
    Gettinger, Scott
    Hellmann, Matthew D.
    Chow, Laura Q. M.
    Borghaei, Hossein
    Antonia, Scott
    Brahmer, Julie R.
    Goldman, Jonathan W.
    Gerber, David E.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott A.
    Young, Tina C.
    Li, Xuemei
    Geese, William J.
    Rizvi, Naiyer
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1363 - 1372
  • [10] Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
    Zhong, Wen-Zhao
    Wang, Qun
    Mao, Wei-Min
    Xu, Song-Tao
    Wu, Lin
    Shen, Yi
    Liu, Yong-Yu
    Chen, Chun
    Cheng, Ying
    Xu, Lin
    Wang, Jun
    Fei, Ke
    Li, Xiao-Fei
    Li, Jian
    Huang, Cheng
    Liu, Zhi-Dong
    Xu, Shun
    Chen, Ke-Neng
    Xu, Shi-Dong
    Liu, Lun-Xu
    Yu, Ping
    Wang, Bu-Hai
    Ma, Hai-Tao
    Yan, Hong-Hong
    Yang, Xue-Ning
    Zhou, Qing
    Wu, Yi-Long
    LANCET ONCOLOGY, 2018, 19 (01): : 139 - 148
12345